Yahoo
Toronto - Delayed Quote CAD

Profound Medical Corp. (PRN.TO)

10.14 +0.50 (+5.19%)
At close: November 6 at 3:59:30 PM EST
Chart Range Bar
Loading chart for PRN.TO
  • Previous Close 9.64
  • Open 9.60
  • Bid 9.00 x --
  • Ask 10.20 x --
  • Day's Range 8.60 - 10.19
  • 52 Week Range 6.52 - 12.40
  • Volume 48,619
  • Avg. Volume 15,101
  • Market Cap (intraday) 371.396M
  • Beta (5Y Monthly) 0.56
  • PE Ratio (TTM) --
  • EPS (TTM) -1.37
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Neutral

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.

www.profoundmedical.com

162

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

PRN.TO
2.32%
S&P/TSX Composite index (^GSPTSE)
12.31%

1-Year Return

PRN.TO
21.44%
S&P/TSX Composite index (^GSPTSE)
18.89%

3-Year Return

PRN.TO
22.48%
S&P/TSX Composite index (^GSPTSE)
80.53%

5-Year Return

PRN.TO
27.83%
S&P/TSX Composite index (^GSPTSE)
66.80%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 13.75M
Earnings -10.8M
Profit Margin -78.56%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-10M
-5M
0
5M
10M
-300.0%
-200.0%
-100.0%

Analyst Insights

View More

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 1/7/2026
Analyst Lake Street
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 11 -> 12

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -171.56%

  • Return on Assets (ttm)

    -39.46%

  • Return on Equity (ttm)

    -73.53%

  • Revenue (ttm)

    19.09M

  • Net Income Avi to Common (ttm)

    -32.74M

  • Diluted EPS (ttm)

    -1.37

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    38.27M

  • Total Debt/Equity (mrq)

    14.82%

  • Levered Free Cash Flow (ttm)

    -24.82M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: